Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

doi:10.1136/annrheumdis-2019-216118corr1

Article metrics

XML

Miscellaneous

Correction: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Online download statistics by month:

Online download statistics by month: May 2020 to April 2023

	Abstract	Full	Pdf
May 2020	156	169	25
Jun 2020	113	106	38
Jul 2020	38	37	18
Aug 2020	23	22	6
Sep 2020	28	26	12
Oct 2020	7	7	3
Nov 2020	10	9	8
Dec 2020	22	21	8
Jan 2021	19	18	5
Feb 2021	17	16	11
Mar 2021	15	14	8
Apr 2021	13	13	6
May 2021	40	40	5
Jun 2021	95	95	10
Jul 2021	35	35	7
Aug 2021	10	10	5
Sep 2021	15	15	8
Oct 2021	29	29	25
Nov 2021	14	12	20
Dec 2021	26	26	1
Jan 2022	17	16	4
Feb 2022	12	12	2
Mar 2022	23	23	5
Apr 2022	23	23	5
May 2022	47	46	12
Jun 2022	23	23	4
Jul 2022	14	16	4
Aug 2022	25	25	1
Sep 2022	26	26	7
Oct 2022	18	18	4
Nov 2022	9	9	2
Dec 2022	10	8	7
Jan 2023	8	7	7
Feb 2023	44	44	7
Mar 2023	6	6	5
Apr 2023	2	2	6
Total	1032	1024	311

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: May 2020 to April 2023

Read the full text or download the PDF:

Log in using your username and password